FOXD1 and prostate carcinoma: Moreover, there was no analysis of the clinical correlation between FOXD1 expression and glycolysis-related molecule levels (e.g., HK-2 and LDHA) in clinical prostate cancer samples, which weakens the clinical translational value of the study’s findings.